Loading organizations...
Key people at Vault Pharma.
Vault Pharma is a biotechnology company advancing immune medicines through its proprietary platform. This platform leverages the human vault particle, a naturally occurring nanostructure, to deliver targeted peptide payloads. By harnessing these biological carriers, the company aims to enable specific immune signaling for therapeutic applications.
The company was founded in 2013, building upon the foundational work of Dr. Leonard Rome, a Professor at the David Geffen School of Medicine at UCLA, who discovered the vault particle. Dr. Rome's insight into the biological functions and structural capabilities of these particles formed the core technology. Oliver Foellmer leads the company as President and CEO.
Vault Pharma’s product pipeline focuses on addressing unmet medical needs, particularly in solid tumors and women’s health. The company’s vision is to develop a new generation of targeted immunotherapies that utilize inherent biological mechanisms to achieve more effective and precise patient treatments.
Key people at Vault Pharma.
Vault Pharma is a preclinical-stage biotech company developing precision immunotherapies using naturally occurring vault particles—nanoscale barrel-shaped structures found in human cells—to deliver antigens and immune-modulating agents for oncology, autoimmune diseases, and women's health issues like pelvic pain and infertility from Chlamydia.[1][2][5] It targets "cold to hot" tumor conversion by enhancing T-cell responses to patient-specific antigens, serving cancer patients, those with autoimmune conditions, and women seeking therapeutic/preventive vaccines, while solving challenges in targeted drug delivery and reliable immune activation amid a $35B+ immune oncology market.[2][5] The company has raised under $5M in funding, holds 16 granted patents exclusively licensed from UCLA, and is one of 12 portfolio companies of Multiverse Investment Fund I, housed at UCLA's CNSI Magnify incubator, but faces funding hurdles in the "valley of death" for clinical trials.[1][2][4]
Vault Pharma emerged from UCLA research on vault particles, mysterious ribonucleoprotein complexes discovered in the 1980s and extensively studied by co-founder Leonard H. Rome, PhD, a distinguished professor of biological chemistry and associate director of the California NanoSystems Institute (CNSI).[2][3][4][5] Rome, known as the "vault guy," identified vaults' immune-alert properties and potential as a delivery platform after decades of basic research, including publications like "A Vaulted Mystery" in The Scientist.[2][4][5] The company launched in 2013 when UCLA reclaimed IP from a prior licensee that abandoned vault-based cancer drug delivery; Rome co-founded Vault Pharma to advance it, initially partnering with Protein Sciences for production before a 2018 acquisition disrupted progress.[4]
Early traction included COVID-19 vaccine development in 2020 with UCLA labs led by Otto O. Yang and Jeff F. Miller, positioning vaults to package SARS-CoV-2 proteins.[3] Pivotal moments feature board additions like Chairman Dr. Jack Kavanaugh (cellular therapies expert) and Vice Chair Dr. Larry Couture in a recent announcement by founder Dr. Leonard Rose (likely Rome), plus scientific advisors Dr. James Mulé and Dr. Antoni Ribas.[1][5] Under CEO Oliver Foellmer, the team refined baculovirus-based vault production for clinical-grade payloads like CCL21 and NY-ESO-1 antigens.[4][5]
Vault Pharma stands out through its proprietary vault particle platform, leveraging nature's design for superior immune targeting:
Vault Pharma rides the explosive immune oncology wave, where therapies harnessing T-cells against solid tumors and pathogens are projected to surpass $35B annually by 2024, amplified by post-COVID demand for versatile nanoparticle platforms.[2][3] Timing aligns with biotech's shift to precision delivery amid gene therapy challenges (e.g., viral stuffing experiments) and cooling VC funding, positioning vaults as a non-viral, ubiquitous human-derived alternative to liposomes or adenoviruses for safer, tunable responses.[4][5] Market forces like rising autoimmune/infectious disease burdens and "valley of death" funding gaps favor its UCLA-backed, patent-protected tech, influencing the ecosystem by enabling collaborations that could standardize vault-based vaccines and expand women's health immunology beyond current limits.[1][2][4]
Vault Pharma's path hinges on raising ~$10M for a pivotal CCL21-loaded vault trial in late-stage cancer, proving safety/efficacy to escape preclinical limbo amid biotech funding chills.[4] Success could unlock Phase 1 data by 2026-2027, scaling to multi-IND pipeline in oncology/autoimmunity via partnerships, propelled by trends like AI-optimized antigens and combo immunotherapies. Its influence may grow as a platform leader if trials validate "cold-to-hot" shifts, potentially licensing vaults ecosystem-wide—echoing its origins in nature's elegant design to redefine immune precision from lab benches to global therapies.[2][4][5]
